Biopharma News Round Up
This week's biopharma news was led by four FDA drug approvals, a run of retinal and ophthalmic readouts, and a cluster of programme failures: argenx in Sjogren's, ArriVent in lung cancer, Nuvig in CIDP and Caribou winding down its CAR-T pipeline.
BY RXCLARITY
Oncology
New data on Revolution Medicines' daraxonrasib showed a lower response rate in patients with the most common KRAS mutation in pancreatic cancer vs the overall trial population.
Competitors impacted: Amgen (Lumakras), Mirati/BMS (Krazati), and other KRAS-pancreatic cancer developers may benefit from weaker daraxonrasib response in the largest mutation subgroup.
FDA Type B meeting provided HCW Biologics clear guidance to finalize its IND application for a lead T-cell engager, supporting a first-in-human study in solid tumors.
Competitors impacted: Solid-tumor T-cell engager developers; no clear direct competitor before IND clearance.
FDA approved Roche's Tecentriq (atezolizumab) in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, its twelfth US indication.
Competitors impacted: MSD (Keytruda), BMS (Opdivo), and adjuvant-colon-cancer immunotherapy developers could face added competition.
Pfizer secured FDA approval for Tukysa plus HER2 antibodies as first-line maintenance in advanced HER2+ breast cancer, showing significant delay in disease progression.
Competitors impacted: AstraZeneca/Daiichi Sankyo (Enhertu), Roche (Perjeta/Herceptin), and other HER2-positive breast-cancer regimen developers.
Halozyme wins Dutch patent ruling blocking Merck from selling subcutaneous Keytruda in several European countries.
Competitors impacted: Merck is directly impacted; subcutaneous PD-(L)1 delivery competitors may also face higher IP barriers in Europe.
New clinical data show Vaccinex's pepinemab reshapes the tumor immune environment in neoadjuvant melanoma, supporting a coordinated immune attack on cancer.
Competitors impacted: Neoadjuvant melanoma immunotherapy developers, principally BMS and MSD; clinical relevance remains early.
Propanc Biopharma reports preclinical data showing PRP achieves 90% tumor growth inhibition in pancreatic cancer models with deep tumor control, fewer metastases, and chemo re-sensitization, contrasting with RAS inhibition alone.
Competitors impacted: KRAS-inhibitor developers in pancreatic cancer could face a potential differentiated approach; preclinical only.
MAIA Biotechnology completes Part C enrollment of THIO-101 Phase 2 and reaches 65% of its 2026 enrollment target for the pivotal THIO-104 Phase 3 study in NSCLC.
Competitors impacted: NSCLC developers including AstraZeneca, Merck, BMS, and BeiGene; no direct impact until pivotal data.
MimiVax's SurVaxM peptide cancer vaccine narrowly missed its Phase 2b primary endpoint for glioblastoma, though researchers see enough signal to continue exploring benefit for certain patients.
Competitors impacted: Other glioblastoma vaccine and immunotherapy developers may benefit from reduced competitive pressure.
Caribou Biosciences discontinued all clinical development and substantially reduced its workforce after failing to secure funding, shelving two allogeneic CAR-T programs including vispa-cel and putting the company on course to wind down.
Competitors impacted: Allogeneic CAR-T competitors - including Allogene, CRISPR Therapeutics, and Cellectis - may face one fewer competing program.
ArriVent's lead lung cancer drug firmonertinib, an EGFR inhibitor, failed its Phase 3 trial, casting doubt on the program's future.
Competitors impacted: EGFR-mutant NSCLC competitors, notably AstraZeneca (Tagrisso), may benefit from reduced firmonertinib competition.
Regeneron presents longer-term survival outcomes from the Phase 3 C-POST trial of adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.
Competitors impacted: MSD, BMS, and other adjuvant immuno-oncology developers in high-risk cutaneous squamous-cell carcinoma.
Kairos Pharma is moving prostate cancer drug ENV-105 into an earlier line of treatment after midphase survival data supported expansion.
Competitors impacted: Advanced-prostate-cancer developers, including Pfizer/Astellas, Novartis, and Bayer; direct overlap depends on ENV-105's treatment setting.
Genmab's FRa-directed ADC Rina-S achieved a 45.9% objective response rate in platinum-resistant ovarian cancer patients.
Competitors impacted: Ovarian-cancer ADC developers, including ImmunoGen/AbbVie (Elahere) and other folate receptor-alpha programs.
FDA clears the IND for Medicovestor's MC001 ADC, enabling the company to initiate an international Phase 1 pancreatic cancer trial.
Competitors impacted: Pancreatic-cancer ADC developers; no clear direct competitor at IND stage.
Hematology
BMS reports that its recently approved Zenbexus (iberdomide) regimen more than doubled PFS versus daratumumab/bortezomib/dexamethasone in multiple myeloma.
Competitors impacted: Johnson & Johnson (Darzalex), Sanofi (Sarclisa), and myeloma regimen developers.
Cullinan Therapeutics dosed the first patient in its pivotal Phase 2 study of CLN-049, a FLT3 T cell engager, for relapsed/refractory AML.
Competitors impacted: AML T-cell engager and FLT3-targeted therapy developers, including Amgen and Astellas; early-stage.
vTv Therapeutics receives FDA Orphan Drug Designation for HPPD in sickle cell disease, supporting partnering discussions while the company prioritizes its lead T1D program cadisegliatin.
Competitors impacted: Sickle-cell-disease developers including Vertex/CRISPR, Bluebird bio, and Novartis; orphan designation alone does not establish competitive advantage.
CHARM Therapeutics dosed the first patient and fully enrolled the first cohort in its Phase I/II trial of menin inhibitor CHM-029 for AML.
Competitors impacted: AML menin-inhibitor developers, particularly Kura Oncology and Syndax.
First patient enrolled in a Phase 1b/2 study combining bexobrutideg with venetoclax in chronic lymphocytic leukemia.
Competitors impacted: CLL developers including AbbVie (Venclexta), BeiGene (Brukinsa), AstraZeneca (Calquence), and other BTK/BCL-2 combinations.
Epkinly (epcoritamab) plus R-CHOP cut the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL, positioning the T-cell engager as a first-line challenger to Roche's Polivy.
Competitors impacted: Roche (Polivy) is the clearest directly affected first-line DLBCL competitor.
FDA extended Novo Nordisk's Frehemgo review due to manufacturing site corrections, delaying its US market entry for hemophilia A.
Competitors impacted: Hemophilia A competitors - including Roche (Hemlibra), Sanofi/Sobi (Altuviiio), and Takeda - may benefit from delayed Frehemgo entry.
Lilly's Jaypirca gained a label expansion.
Competitors impacted: CLL and mantle-cell-lymphoma competitors, including AbbVie/Johnson & Johnson (Imbruvica), AstraZeneca (Calquence), and BeiGene (Brukinsa).
Neurology
New pediatric, adult and real-world efficacy and safety data for daridorexant in insomnia were presented at Sleep Europe 2026, expanding the clinical evidence base.
Competitors impacted: Insomnia competitors including Eisai (Dayvigo), Merck (Belsomra), and other dual orexin receptor antagonist developers.
Nuvig Therapeutics halted development of its lead fusion protein NVG-2089 in CIDP after determining the program would not advance quickly enough, ending one of two ongoing studies for the candidate.
Competitors impacted: CIDP therapy developers, including argenx (Vyvgart Hytrulo), CSL (Hizentra), Takeda, and UCB, may face less emerging competition.
Cerevance will discuss Phase 3 data with the FDA to chart a regulatory path for its Parkinson's drug solengepras.
Competitors impacted: Parkinson's-disease developers including AbbVie, Neurocrine, and UCB; FDA discussion is not a competitive inflection by itself.
Novartis will present Phase III REMODEL-1 and REMODEL-2 results for BTK inhibitor remibrutinib in multiple sclerosis at MSToronto2026.
Competitors impacted: Multiple-sclerosis BTK inhibitor developers, including Sanofi, Merck KGaA, and Roche.
Jupiter Neurosciences doses first patient in its Phase 2a RESET trial of JOTROL in Parkinson's disease, advancing the study evaluating safety and biomarkers.
Competitors impacted: Parkinson's-disease developers; no clear direct competitor at Phase 2a initiation.
ProMIS Neurosciences names Ivana Rubino, Ph.D., as Chief Commercial Officer, adding a seasoned Alzheimer's executive from Biogen and Roche to lead commercialization and launch readiness.
Competitors impacted: Alzheimer's-disease competitors, including Eisai/Biogen and Lilly; executive hiring has no direct product-level impact.
ATH434 50 mg slowed functional decline in multiple system atrophy by around 52% versus placebo at Week 52 in Phase 2 data presented at a major congress.
Competitors impacted: Multiple-system-atrophy developers, including UCB and other alpha-synuclein-targeting programs.
Ophthalmology
Preclinical results at Sheba Medical Center showed NurExone's exosome-based lead candidate promoted retinal recovery in an optic nerve injury model, supporting advancement toward a larger-animal study.
Competitors impacted: Optic-nerve-regeneration and exosome/cell-therapy developers; preclinical, no direct commercial effect.
First-in-human data shows ER-100 well-tolerated through Day 56 in glaucoma patients, supporting dose escalation in the Phase 1 trial.
Competitors impacted: Glaucoma gene-therapy and neuroprotection developers; early clinical stage.
Six-month data for Iantrek's bio-reinforced canaloplasty show 37% IOP reduction in glaucoma patients.
Competitors impacted: Glaucoma device/procedure competitors, including Alcon, Glaukos, and New World Medical.
iRegene Therapeutics receives US and China clearance to trial NouvSight001, an off-the-shelf cell therapy for retinitis pigmentosa.
Competitors impacted: Retinitis-pigmentosa cell/gene-therapy developers, including jCyte and MeiraGTx.
PulseSight presented Phase I clinical efficacy data for PST-611 in dry AMD and geographic atrophy at EURETINA, showing potential as a non-viral gene therapy breakthrough.
Competitors impacted: Dry-AMD/geographic-atrophy gene-therapy developers, including Apellis, Iveric Bio/Astellas, and others; Phase 1 evidence remains preliminary.
Harrow closed its acquisition of TYRVAYA, the first FDA-approved nasal spray for dry eye, adding a drop-free treatment to its ocular surface franchise.
Competitors impacted: Dry-eye competitors including Bausch + Lomb (Xiidra), Viatris (Miebo), and AbbVie (Restasis).
Rare disease
Korro Bio dosed the first cohort in the Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
Competitors impacted: Urea-cycle-disorder and hepatic-encephalopathy developers; early-stage with no clear direct impact.
Shionogi is acquiring IntraBio in a transaction reported at around $2.2 billion in total potential consideration, about $1.1 billion upfront plus up to around $1.1 billion in milestones, gaining the approved oral rare disease drug Aqneursa (levacetylleucine) for Niemann-Pick disease type C.
Competitors impacted: Rare-neurology competitors in Niemann-Pick type C and adjacent lysosomal disorders; commercial impact depends on deal completion.
Capricor's HOPE-3 open-label extension shows deramiocel slowed upper limb decline by 76% in Duchenne muscular dystrophy patients at the 24-month crossover analysis.
Competitors impacted: Duchenne-muscular-dystrophy competitors, including Sarepta, PTC Therapeutics, NS Pharma, and Solid Biosciences.
Epicrispr reports encouraging updated data from its Phase 2 trial of EPI-321, an epigenetic editing therapy for FSHD, with 12 patients dosed.
Competitors impacted: FSHD developers, including Avidity, Dyne Therapeutics, and Facioscapulohumeral muscular dystrophy gene-therapy programs.
Rezolute announced the FDA recommended a Pre-BLA meeting for its congenital hyperinsulinism program, signaling regulatory alignment toward a potential BLA submission.
Competitors impacted: Congenital-hyperinsulinism developers, including Zealand Pharma and Crinetics; regulatory engagement is not approval.
Cardiovascular
New Launch-HTN trial analyses show 46% of difficult-to-treat hypertension patients on lorundrostat 50 mg achieved the <130 mmHg systolic BP target at 12 weeks.
Competitors impacted: Resistant-hypertension developers, including AstraZeneca (baxdrostat) and Idorsia (aprocitentan).
Editas Medicine received FDA clearance to begin a Phase 1/2 trial of its gene-editing asset EDIT-401 for LDL-C reduction in hyperlipidemia patients.
Competitors impacted: LDL-C gene-editing and RNA-therapy developers, including Verve, CRISPR Therapeutics, and Regeneron.
FDA cleared Abbott's updated CardioMEMS HF System enabling at-home heart readings via the CardioGuide HF App.
Competitors impacted: Heart-failure remote-monitoring competitors, including Medtronic and Boston Scientific.
New analyses show substantial antihypertensive efficacy of aprocitentan in patients with obesity and across the cardiometabolic disease spectrum.
Competitors impacted: Resistant-hypertension developers, notably Mineralys and AstraZeneca.
Dermatology
Sagimet announces positive 52-week Phase 3 open-label extension results for denifanstat in moderate-to-severe acne, to be presented at a dermatology conference.
Competitors impacted: Acne-treatment developers, including Bausch Health/Ortho Dermatologics, Galderma, and Cassiopea.
Alumis reports Phase 3 data showing Envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality of life measures.
Competitors impacted: Psoriasis competitors, including Amgen (Otezla), BMS (Sotyktu), and TYK2/IL-23 developers.
FDA approved Novartis' Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, expanding the oral BTK inhibitor to cover both major forms of chronic hives, a first for the field.
Competitors impacted: Chronic-inducible-urticaria competitors, including Roche/Genentech (Xolair) and other antihistamine/biologic developers.
Gastrointestinal
AltruBio will present new Phase 2a data from its ALTB-268 ASCEND UC2a trial at UEG Week 2026, disclosing results from the ulcerative colitis study.
Competitors impacted: Ulcerative-colitis developers, including AbbVie, Lilly, BMS, Takeda, and Johnson & Johnson.
Madrigal publishes a pre-specified MAESTRO-NASH secondary analysis showing Rezdiffra efficacy is consistent across common MASH genetic risk variants.
Competitors impacted: MASH competitors, including Novo Nordisk, Eli Lilly, Akero, 89bio, and Intercept.
Assembly Biosciences reports positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD, with its pharmacodynamic analysis receiving a Poster of Distinction.
Competitors impacted: Hepatitis B and antiviral developers, including Gilead, Arbutus, and Roche; Phase 1a data are early.
Infectious diseases
Vir Biotechnology appoints David Liu, M.D., Ph.D., as chief medical officer to lead late-stage push for hepatitis D combo.
Competitors impacted: Hepatitis D developers, especially Gilead and Eiger/related programs; executive appointment has no direct impact.
MHRA revoked IXCHIQ's UK marketing authorization following a CHM benefit-risk review based on prior safety data, though no new safety signal was identified.
Competitors impacted: Chikungunya-vaccine competitors, notably Bavarian Nordic, may benefit from reduced UK competition.
Vaxcyte's 31-valent pneumococcal vaccine VAX-31 met all primary endpoints in the Phase 3 OPUS-1 trial, showing non-inferiority to Prevnar 20 and Capvaxive.
Competitors impacted: Pfizer (Prevnar 20) and Merck (Capvaxive) are the clearest directly affected pneumococcal-vaccine competitors.
Metabolic
Neil Aubuchon departs as Viking's CCO after just nine months, raising questions about obesity drug strategy, while Gilead recruits a BeOne executive to lead China expansion.
Competitors impacted: Obesity-drug competitors including Lilly, Novo Nordisk, Amgen, and Roche/Carmot; management turnover does not directly change competitive position.
Zealand Pharma's amylin analog petrelintide delivers positive Phase 2 ZUPREME-2 topline results in people with overweight or obesity and type 2 diabetes.
Competitors impacted: Obesity and diabetes developers, particularly Lilly, Novo Nordisk, Amgen, Viking, and Structure Therapeutics.
vTv Therapeutics completes enrollment in the Phase 3 CATT1 study of cadisegliatin for type 1 diabetes, with topline data expected mid 2027.
Competitors impacted: Type 1 diabetes developers, including Vertex, Sana Biotechnology, and other beta-cell or disease-modifying programs.
Psychiatry
FDA approved Teva's WELTRUZA (olanzapine) extended-release injectable suspension, the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.
Competitors impacted: Long-acting antipsychotic competitors, including Alkermes, Johnson & Johnson, Otsuka/Lundbeck, and AbbVie.
Newron is holding a management call to update on the FDA clinical hold affecting its Phase 3 ENIGMA-TRS trial of evenamide for treatment-resistant schizophrenia.
Competitors impacted: Treatment-resistant-schizophrenia developers; clinical hold raises uncertainty but does not directly alter competitors' positions.
Neurosterix completes Phase 1 studies of its oral NMDA receptor modulator NTX-253, clearing the way for Phase 2 development in schizophrenia.
Competitors impacted: Schizophrenia NMDA-modulator developers, including Neurocrine and other glutamatergic-approach companies.
Respiratory
Endeavor BioMedicines reported positive Phase 2 data for ENV-101 in IPF, claiming the drug can reverse the chronic lung disease.
Competitors impacted: Idiopathic-pulmonary-fibrosis developers, including Boehringer Ingelheim, Roche, United Therapeutics, and FibroGen.
Diagnostics
BillionToOne's Northstar Response assay shows 94% concordance with tumor-informed ctDNA testing in a peer-reviewed head-to-head study, with discordant cases favoring the tissue-free assay.
Competitors impacted: Tumor-informed ctDNA competitors, including Natera (Signatera), Guardant Health, and Foundation Medicine/Roche.
Endocrinology
Ascendis presents combined Phase 2/3 data at ASBMR showing TransCon PTH normalizes bone mass and microarchitecture in hypoparathyroidism patients over 5 years.
Competitors impacted: Hypoparathyroidism competitors, including Takeda and Amolyt Pharma/AZ; long-term data could reinforce TransCon PTH differentiation.
Immunology
A DSMB recommended stopping argenx's Phase 3 UNITY study of Vyvgart Hytrulo in Sjogren's disease for futility, a surprise setback that removes a key expansion opportunity for the FcRn blocker.
Competitors impacted: Sjögren's-disease developers - including Novartis, UCB, and other B-cell/FcRn-pathway programs - may face less competitive pressure.
Nephrology
One04 Therapeutics will present interim Phase 1 data for CPV-104 in C3 glomerulopathy at ASN Kidney Week, offering an early look at the drug's profile in this rare kidney disease.
Competitors impacted: C3 glomerulopathy developers, including Novartis, Apellis, and Roche; interim Phase 1 data are too early for direct impact.
Corporate and policy
LB Pharmaceuticals grants inducement equity awards to its new Chief Medical Officer and Chief Financial Officer upon their hiring.
Competitors impacted: No clear direct competitor; personnel-related event.
BD appointed Ferass Abuzaina as Worldwide President of its Surgery business unit.
Competitors impacted: Surgical-device competitors such as Medtronic, Stryker, and Johnson & Johnson; leadership change has no immediate direct impact.
Tevogen signed a non-binding letter of intent to evaluate a potential acquisition of HRK Healthcare LLC.
Competitors impacted: No clear direct competitor; non-binding transaction evaluation.
New PDUFA deal gives FDA dedicated funding to rehire reviewers after HHS layoffs, supporting drug review capacity.
Competitors impacted: Broadly benefits drug developers awaiting review; not a company-specific competitor impact.
UK drug marketing watchdog found CSL Seqirus had multiple prolonged deficiencies in its systems, governance and oversight.
Competitors impacted: Vaccine and plasma-therapy competitors may benefit if governance findings affect commercial execution; no direct product effect established.
Stryker appoints veteran Spencer Stiles as CEO following Kevin Lobo's move to the board.
Competitors impacted: Orthopedic and surgical-device peers including Zimmer Biomet, Medtronic, and J&J; leadership succession has no immediate direct impact.
Remix Therapeutics appointed Michael Landsittel to its Board of Directors.
Competitors impacted: No clear direct competitor; board appointment.
Oak Hill Bio appoints Joerg Hipp, PhD as Chief Translational Science Officer; he previously led development of the company's lead asset rugonersen.
Competitors impacted: No clear direct competitor; executive appointment.
Entera Bio adds former Gilead and Amgen executive Laura Hamill to its board, bringing over 35 years of commercial and blockbuster therapy expertise.
Competitors impacted: No clear direct competitor; board appointment.
GE HealthCare acquires Sofie Biosciences for $945M to expand radiopharmaceutical manufacturing and distribution for PET imaging.
Competitors impacted: PET-radiopharmaceutical manufacturing and distribution competitors, including Siemens Healthineers, Curium, and Cardinal Health.
The UK MHRA announced a policy to continuously monitor all AI-based medical devices, marking a shift from periodic to constant oversight.
Competitors impacted: AI-medical-device developers broadly; enhanced monitoring may raise compliance demands across competing suppliers.
Richard Bonneau, Genentech's global head of AI for drug discovery, has departed the Roche unit effective immediately, marking another high-profile leadership exit.
Competitors impacted: AI-drug-discovery competitors may gain talent-recruitment opportunity; no direct asset-level impact.
PMV Pharmaceuticals appoints Matt Eckler, Ph.D., to its Board of Directors.
Competitors impacted: No clear direct competitor; board appointment.
FDA approved additional US manufacturing capacity for Alvotech's SIMLANDI biosimilar to Humira, authorizing both drug substance suites at the Reykjavik facility and confirming satisfactory resolution of prior inspection findings.
Competitors impacted: AbbVie (Humira) and other adalimumab/biosimilar suppliers, including Amgen, Sandoz, Boehringer Ingelheim, and Organon.
FDA warned Evolus over an Instagram reel that blurred the line between its prescription Jeuveau product and consumer cosmetics.
Competitors impacted: Aesthetic-neuromodulator competitors, including AbbVie (Botox Cosmetic), Galderma (Dysport), and Revance/Crown (Daxxify), may benefit from promotional scrutiny.
Novartis inked a $7.8B mRNA deal.
Competitors impacted: mRNA platform developers and partners; the source names neither the counterparty nor the therapeutic focus, so no competitor can be identified.
Other
Equillium received Australian regulatory clearance to start a first-in-human Phase 1 trial of EQ504, with dosing expected by November 2026 and topline data about six months later.
Competitors impacted: No clear direct competitor; first-in-human autoimmune/inflammation program remains very early.
FDA grants 510(k) clearance to TELA Bio's Liora Monofilament Scaffold for soft tissue reinforcement.
Competitors impacted: Soft-tissue-reinforcement competitors, including BD, Medtronic, and Johnson & Johnson.
Orion Pharma dosed the first patient in a Phase 1/2 trial of ODM-216, the company's first biologic candidate to reach clinical testing.
Competitors impacted: Biologic developers in the asset's undisclosed indication; no clear direct competitor at trial start.
Forward Therapeutics reported positive Phase 1 clinical and preclinical data for FT2109, an oral TNFR1 signaling inhibitor, supporting advancement into Phase 2.
Competitors impacted: TNFR1/inflammation-pathway developers; Phase 1 and preclinical data do not establish direct competitive impact.
The USPTO granted Satellos a composition of matter patent for forazapadin, securing IP protection through 2044 as the drug progresses in Phase 2.
Competitors impacted: Muscular-dystrophy developers, including Sarepta, PTC, and Edgewise; patent grant strengthens Satellos' IP position rather than immediate market share.
Source: Curated news by sentiment and category from FierceBiotech, FiercePharma, Endpoints News, BioPharma Dive, and GlobeNewswire linked to RxClarity records.